Vistagen Therapeutics Inc Stock Price, News & Analysis

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has scheduled its fiscal year 2026 first quarter earnings conference call for August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The company will discuss its financial results for the quarter ended June 30, 2025, and provide updates on its corporate activities. The webcast will be accessible through the Investors section of Vistagen's website and will remain available for at least 90 days after the event.

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. CEO Shawn Singh will engage in a fireside chat on Tuesday, July 29, at 10 a.m. Eastern Time.

The company, which specializes in developing intranasal product candidates through nose-to-brain neurocircuitry, will make the fireside chat available via livestream for registered investors, with a recording accessible on the BTIG conference portal afterward. One-on-one meetings with management can be arranged through BTIG representatives.

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has received two significant workplace recognitions in 2025. The company earned the Platinum Bell Seal for Workplace Mental Health from Mental Health America for the third consecutive year, achieving a score between 92-100%. Additionally, Vistagen was certified as a Great Place to Work® for the second consecutive year.

The Platinum Bell Seal recognition places Vistagen among an elite group, as only 40% of assessed employers meet the certification standards. The company's workplace culture evaluation focused on four key areas: workplace culture, benefits, compliance, and wellness programs. According to Great Place to Work® data, certified company employees are 93% more likely to look forward to work and twice as likely to report fair treatment in pay, profit sharing, and promotion opportunities.

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company, has appointed Elissa Cote as Chief Corporate Development Officer. With nearly 30 years of experience, Cote will lead strategic opportunities and partnerships for Vistagen's pherine platform, which includes five novel intranasal candidates targeting six prevalent disorders.

Prior to joining Vistagen, Cote served as fractional Chief Business Officer and held senior roles at Mallinckrodt Pharmaceuticals, Sucampo Pharmaceuticals, and MedImmune. As part of her appointment, she received an incentive option to purchase 150,000 shares of Vistagen's common stock, vesting over four years.

Vistagen (VTGN) reported its fiscal year 2025 financial results and provided updates on its clinical pipeline. The company's lead program, fasedienol for social anxiety disorder (SAD), expects PALISADE-3 Phase 3 trial results in Q4 2025 and PALISADE-4 results in H1 2026. With over 30 million U.S. adults affected by SAD, successful trial results could support an NDA submission. The company showcases five intranasal pherine candidates targeting six disorders, including itruvone for major depressive disorder and PH80 for menopausal hot flashes. Financial results show R&D expenses increased to $39.4M from $20.0M, G&A expenses rose to $17.1M from $14.1M, and net loss widened to $51.4M from $29.4M. Cash position stands at $80.5M as of March 31, 2025.

Vistagen (VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and developing intranasal pherine products, has scheduled its fiscal year 2025 financial results conference call for June 17, 2025, at 2:00 PM PT/5:00 PM ET. The company will present its financial performance for the fiscal year ended March 31, 2025, along with a corporate update. The conference call will be accessible via webcast through the company's website under the 'Events' section in the Investors area. Participants can register online to receive dial-in information and are advised to join 15 minutes before the start time. A replay of the webcast will be available on Vistagen's website approximately 24 hours after the call for at least 30 days.

Vistagen (VTGN) has provided an update on its PALISADE Phase 3 Program for fasedienol, a novel intranasal treatment for social anxiety disorder (SAD). The company confirms PALISADE-3 trial remains on track for topline data in Q4 2025, while PALISADE-4 results are expected in H1 2026. Following positive results from PALISADE-2 in 2023, both ongoing trials maintain the same public speaking challenge design with enhanced protocols for site training, surveillance, and subject selection. The company believes success in either PALISADE-3 or PALISADE-4, combined with positive PALISADE-2 results, could support an FDA New Drug Application for fasedienol in treating SAD.

Vistagen (VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and developing intranasal pherine products, has announced its participation in the upcoming Jefferies 2025 Global Life Sciences Conference in New York. The company's CEO, Shawn Singh, will engage in a fireside chat on June 5, 2025, at 11:40 a.m. ET. Investors can access the presentation through a live webcast on Vistagen's website's Investors section, with a replay available afterward.

[]

Vistagen (VTGN), a clinical-stage biopharmaceutical company focused on neuroscience, will present two posters at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The first presentation on May 28 will discuss the age of onset of Social Anxiety Disorder (SAD) from fasedienol clinical trials. The second presentation on May 29 will explore how itruvone, their investigational pherine for major depressive disorder, affects nasal chemosensory receptors and olfactory bulb physiologic activation through specific biomarkers. Both posters will be available on Vistagen's website on June 2, 2025.